What is HC Wainwright’s Forecast for Absci Q1 Earnings?

Absci Co. (NASDAQ:ABSI) – HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Absci in a report released on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.27) per share for the quarter, down from their previous forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci’s Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

Several other research analysts also recently weighed in on ABSI. Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Absci in a research report on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $10.00 price objective on shares of Absci in a research report on Thursday. Finally, KeyCorp lowered their price objective on shares of Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.57.

Absci Price Performance

Shares of NASDAQ ABSI opened at $3.01 on Friday. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci has a 52 week low of $2.45 and a 52 week high of $6.72. The business’s 50 day moving average price is $3.86 and its 200 day moving average price is $3.66. The firm has a market cap of $383.28 million, a P/E ratio of -3.24 and a beta of 2.09.

Absci (NASDAQ:ABSI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The business had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%.

Institutional Investors Weigh In On Absci

A number of institutional investors have recently bought and sold shares of ABSI. PCA Investment Advisory Services Inc. purchased a new position in shares of Absci in the fourth quarter valued at $26,000. Alpha Cubed Investments LLC acquired a new position in Absci during the 4th quarter valued at about $26,000. Ballentine Partners LLC acquired a new position in shares of Absci in the 4th quarter worth approximately $27,000. BNP Paribas Financial Markets acquired a new position in shares of Absci in the 4th quarter worth approximately $28,000. Finally, Verdence Capital Advisors LLC acquired a new position in shares of Absci in the 4th quarter worth approximately $37,000. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.